Skip to main content
Caplight Logo









Aimmed

Aimmed

Private
SeoulHealthcare & Life Scienceshttps://aimmed.co.kr/

Last Round

Corporate Funding

Dec 16, 2022

Total Funding Raised

$17.55M

Company Overview

Aimmed operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Corporate Funding round in December 2022.

Aimmed is a digital healthcare company that develops digital therapeutics and operates integrated health management platforms for insurance, corporate, and senior care services.

Sector

Healthcare & Life Sciences

Verticals

Mental Health, Medical Devices, Patient Engagement

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Usage-Based SaaS

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Aimmed Comparables

Compare Aimmed with similar companies based on industry and business-model similarity.

Aimmed comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
WELT Corp.
88%
HelloBetter
80%
HAII
77%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Aimmed Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingDec 16, 2022
Series AOct 7, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Aimmed Investors

Notable investors and investment history

Aimmed investors
InvestorRounds
TS InvestmentSeries A
Hanwha Asset ManagementSeries A
Korea Investment Private EquitySeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    Monthly visitors increased 73% MoM to 53.9K.

  • Oct 7, 2021

    $15.2M round with Hanwha Asset Management and others.

Book a demo to see all signals

For institutional investors. Book with your work email.

Aimmed Filings

Explore SEC and related filing metadata, where available.

Aimmed filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Aimmed's valuation, stock price, and market status.

Is Aimmed a public or private company?

Aimmed is a private company.

What is the current stock price of Aimmed?

Aimmed is a private company, so its shares have no public market price. Caplight tracks Aimmed's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Aimmed worth (valuation)?

Valuation information for Aimmed is not publicly available.

Can I buy Aimmed stock?

Aimmed shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Aimmed's last funding round?

Aimmed's most recent funding round was Corporate Funding on December 16, 2022.

Who are the main investors in Aimmed?

Key investors in Aimmed include TS Investment, Hanwha Asset Management, Korea Investment Private Equity.

Will Aimmed IPO soon?

No public IPO plans have been announced for Aimmed.

How can I track Aimmed secondary market activity?

Caplight tracks bids, offers, and trades in Aimmed's shares on secondary markets.

Firmographic Details

HeadquartersSeoul
Employee Range38
Year Founded1999
Last FundingDec 16, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?